Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137056 | 0.89 | ALDH1A1 (0.55) | TSHRSMN1; SMN2GLAALDH1A1MAPT | |
| SCHEMBL3481205 | 0.82 | TSHR (0.64) | TSHRSMN1; SMN2GLAALDH1A1MAPT | |
| SCHEMBL6985762 | 0.78 | TSHR (0.57) | TSHRSMN1; SMN2GLAALDH1A1MAPT | |
| SCHEMBL8144060 | 0.77 | MAPT (0.55) | SMN1; SMN2ALDH1A1MAPTKMT2AMAPK1 | |
| SCHEMBL8136193 | 0.77 | RECQL (0.44) | SMN1; SMN2ALDH1A1MAPTTDP1KMT2A | |
| SCHEMBL11989336 | 0.76 | TSHR (0.68) | TSHRSMN1; SMN2GLAALDH1A1MAPT | |
| SCHEMBL8139201 | 0.76 | HPGD (0.53) | SMN1; SMN2ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL13312378 | 0.76 | HPD (0.46) | SMN1; SMN2ALDH1A1MAPTTDP1KMT2A | |
| SCHEMBL16950684 | 0.75 | TSHR (0.71) | TSHRSMN1; SMN2GLAALDH1A1TDP1 | |
| SCHEMBL8136123 | 0.75 | POLB (0.41) | SMN1; SMN2ALDH1A1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| CN-1491216-A | Novel alkylphenylimidazolidine derivatives for the treatment of urinary incontinence | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-21 | — | — | CN | disclosed |
| EP-1362038-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG | 2002-11-14 | — | — | US | disclosed |
| WO-2002064570-A1 | NOVEL ALKYL PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | WO | disclosed |
| EP-0282944-B1 | Pyrazole derivative and herbicide containing it | NISSAN CHEMICAL IND LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5175299-A | Benzoic acid derivatives useful as intermediates for the preparation of herbicidal 4-benzoylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| US-4948887-A | FOR UPLAND FIELDS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4885022-A | Herbicidal pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-12-05 | — | — | US | disclosed |
| EP-0282944-A2 | Pyrazole derivative and herbicide containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169193-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, ADRB2, REN | TSHR 1979/4885SMN1; SMN2 560/4885GLA 2330/4885 |
| US-20050085522-A1 | Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence | AGTR2, F12, UTS2R | TSHR 1522/4885SMN1; SMN2 646/4885GLA 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.